Large gap with delayed quotes
Last quote
07/01/2025
-
16:44:06
|
Bid
07/01/2025 -
16:45:01
|
Bid Volume |
Ask
07/01/2025 -
16:45:01
|
Ask Volume |
---|---|---|---|---|
451.37
+6.17
(
+1.39% )
|
450.93
|
100 |
451.99
|
300 |
Analysis date: 27.06.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 10.06.2025.
Interest
Very weak
Very weak
One star since 20.06.2025.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 23.05.2025 at a price of 436.00.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The forty day technical trend is negative since 06.05.2025.
4wk Rel Perf
-5.30%
-5.30%
The four-week dividend-adjusted underperformance versus SP500 is 5.30%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 10.06.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.55%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.62%.
Mkt Cap in $bn
113.32
113.32
With a market capitalization >$8bn, VERTEX PHARMA INC is considered a large-cap stock.
G/PE Ratio
17.60
17.60
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
18.15
18.15
The estimated PE is for the year 2028.
LT Growth
319.49%
319.49%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
20
20
Over the last seven weeks, an average of 20 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
48
48
For 1% of index variation, the stock varies on average by 0.48%.
Correlation
0.32
0.32
Stock movements are strongly independent of index variations.
Value at Risk
89.96
89.96
The value at risk is estimated at USD 89.96. The risk is therefore 20.39%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
02.01.2002
02.01.2002